Nicholas P Loconte

US Patent:

20130089625, Apr 11, 2013

Filed:

Sep 28, 2012

Appl. No.:

13/631732

Inventors:

Jean-Damien Charrier - Grove, GB
Pierre-Henri Storck - Abingdon, GB
John Studley - Witney, GB
Francoise Yvonne Theodora Marie Pierard - Abingdon, GB
Steven John Durrant - Abingdon, GB
Benjamin Joseph Littler - Carlsbad CA, US
Paul Angell - Carlsbad CA, US
Robert Michael Hughes - San Diego CA, US
David Andrew Siesel - San Diego CA, US
Armando Urbina - San Diego CA, US
Carl Zwicker - Brighton MA, US
Nicholas LoConte - Winthrop MA, US
Timothy Barder - Arlington MA, US

Assignee:

VERTEX PHARMACEUTICALS INCORPORATED - Cambridge MA

International Classification:

C07D 413/14
A61K 45/06
A61N 5/10
A61K 31/4745
A61K 31/7068
A61K 31/497
A61K 33/24

US Classification:

424649, 544405, 51425505, 514 49, 435184, 600 1

Abstract:

The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; solid forms of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors.The compounds of this invention have formula I-1:wherein the variables are as defined herein.Additionally, the compounds of this invention have formula II:or a pharmaceutically acceptable salt thereof, wherein the variables are as defined herein.